Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: a good idea or a grave error?

Balañá C, Etxaniz O, Bugés C, Martínez A.

Medical Oncology Service, Institut Català d’Oncologia Germans Trias i Pujol, Badalona, Barcelona, Spain.

PMID: 21421467 [PubMed - in process]

LinkOut - more resources